Is the “Lean NAFLD/MAFLD/MASLD” nosography construct still clinically useful and scientifically warranted?

Recent changes in steatotic liver disease (SLD) nomenclature, together with a broader view of adiposity and metabolic health, require renewed appraisal of SLD in lean individuals. This review evaluates the clinical relevance of lean nonalcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated fatty liver disease (MAFLD), and metabolic dysfunction-associated SLD (MASLD) by integrating meta-analytic evidence, emerging MAFLD data, and original MASLD studies. Across definitions, while obesity is a risk factor for SLD development and progression, leanness does not confer protection. Lean NAFLD accounts for a substantial share of the global disease burden and is associated with steatohepatitis, advanced fibrosis, cirrhosis, incident diabetes, liver-related and all-cause mortality, and selected extrahepatic outcomes, despite a generally more favorable cardiometabolic profile than obesity-associated disease. Lean MAFLD is less prevalent but clinically important, with evidence of excess liver-related mortality. Early MASLD studies similarly show that body mass index (BMI) can underestimate hepatic, cardiovascular, and survival risk. Genetic, epigenetic, demographic and ethnic factors further shape disease susceptibility and progression. Overall, the evidence supports moving from weight-based classification to risk-based assessment incorporating fibrosis stage, metabolic dysfunction, visceral adiposity, sarcopenia, age, sex, ethnicity and genetic risk. Thus, ‘lean’ should not be regarded as a low-risk state, but as a phenotype in which conventional obesity metrics may obscure clinically meaningful disease. Future studies should harmonize definitions, clarify causal pathways, refine phenotyping beyond BMI, and ensure adequate representation of lean individuals in therapeutic, prognostic, and surveillance studies of all SLD variants.

Authors

Institutions

Publication Details

Journal
Exploration of Medicine
Published
2026-11-19
DOI
https://doi.org/10.37349/emed.2026.1001440
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Is the “Lean NAFLD/MAFLD/MASLD” nosography construct still clinically useful and scientifically warranted?

Ralf Weiskirchen, Amedeo Lonardo
Exploration of Medicine
Liver Disease Diagnosis and Treatment
article

Is the “Lean NAFLD/MAFLD/MASLD” nosography construct still clinically useful and scientifically warranted?

Ralf Weiskirchen, Amedeo Lonardo
article en

Abstract

Recent changes in steatotic liver disease (SLD) nomenclature, together with a broader view of adiposity and metabolic health, require renewed appraisal of SLD in lean individuals. This review evaluates the clinical relevance of lean nonalcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated fatty liver disease (MAFLD), and metabolic dysfunction-associated SLD (MASLD) by integrating meta-analytic evidence, emerging MAFLD data, and original MASLD studies. Across definitions, while obesity is a risk factor for SLD development and progression, leanness does not confer protection. Lean NAFLD accounts for a substantial share of the global disease burden and is associated with steatohepatitis, advanced fibrosis, cirrhosis, incident diabetes, liver-related and all-cause mortality, and selected extrahepatic outcomes, despite a generally more favorable cardiometabolic profile than obesity-associated disease. Lean MAFLD is less prevalent but clinically important, with evidence of excess liver-related mortality. Early MASLD studies similarly show that body mass index (BMI) can underestimate hepatic, cardiovascular, and survival risk. Genetic, epigenetic, demographic and ethnic factors further shape disease susceptibility and progression. Overall, the evidence supports moving from weight-based classification to risk-based assessment incorporating fibrosis stage, metabolic dysfunction, visceral adiposity, sarcopenia, age, sex, ethnicity and genetic risk. Thus, ‘lean’ should not be regarded as a low-risk state, but as a phenotype in which conventional obesity metrics may obscure clinically meaningful disease. Future studies should harmonize definitions, clarify causal pathways, refine phenotyping beyond BMI, and ensure adequate representation of lean individuals in therapeutic, prognostic, and surveillance studies of all SLD variants.

Exploration of MedicineVol. 7
University of Parma (IT), Universitätsklinikum Aachen (DE), RWTH Aachen University (DE)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon